G280 Stock Chart & Stats
€7.70
€0.00(0.00%)
At close: 4:00 PM EDT
€7.70
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.90 - €42.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.23M
Enterprise Value€33.34
Total Cash (Recent Filing)€692.30K
Total Debt (Recent Filing)€3.07M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding6,416,540
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary T‑cell PlatformTevogen's core focus on a precision T‑cell platform provides a durable strategic asset: platform technologies can be applied across multiple indications, enabling pipeline expansion, repeatable R&D processes, and partnership opportunities that support long‑term value beyond any single program.
Lowered Debt BurdenMaterial reduction in debt versus prior years lowers near‑term fixed obligations and interest pressure, extending financial runway and improving optionality for financing or partnerships. That durable improvement reduces immediate solvency strain even as cash burn continues.
Lean, Focused R&D TeamA small, specialized team supports capital efficiency and faster decision cycles in early‑stage biotech. With limited overhead and concentrated expertise, the company can direct scarce cash toward core translational work and maintain operational focus while seeking external funding or partners.
Bears Say
No Revenue / Uncommercialized PortfolioAbsence of revenue indicates the business is pre‑commercial and reliant on external financing to fund operations. Without product sales, the company cannot self‑fund growth or offset R&D spend, which makes long‑term sustainability contingent on successful trials or sustained capital access.
Sustained Cash BurnPersistent negative operating and free cash flow (~$12M TTM) creates ongoing funding needs and increases dilution risk. This durable cash outflow trajectory constrains program pacing, forces prioritization across the pipeline, and heightens dependence on capital markets or partners.
Negative Stockholders' EquityConsistent negative equity signals weakened solvency and limits balance‑sheet flexibility. It impairs borrowing capacity, can raise counterparty concerns, and elevates financing cost or dilution likelihood—structural weaknesses that persist until profitability or capital restructuring occurs.
Tevogen Bio Holdings News
G280 FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was €6.90 and its highest was €42.80 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is €39.23M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Aug 13, 2026 which is in 9 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Jun 03, 2026. The company reported -€1.4 earnings per share for the quarter, beating the consensus estimate of -€2.293 by €0.893.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 6,416,540 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -€1.4 in its last earnings report, beating expectations of -€2.293. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in DE:G280
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―